ACUREX THERAPEUTICS CORPORATION

Biotech · Private

Oral small-molecule inhibitors of 12/15-lipoxygenase enzyme for reducing neuroinflammation in neurodegenerative diseases

Grants
$450K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
1
0 granted · 1 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Discovery of 12/15-lipoxygenase inhibitors to suppress neuroinflammation and slow disease progression in Alzheimer's disease$450,060
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1440ARTBIO——
1441KJ BIOSCIENCES, LLC——
1442Centaurus Therapeutics, Inc.—$2.0M
1443ACUREX THERAPEUTICS CORPORATION——
1444Werewolf Therapeutics, Inc.—$104M
1445TRAILHEAD BIOSYSTEMS, INC.—$30M
1446Saliogen Therapeutics, Inc.—$94M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 1
  • T-type Calcium Channel Antagonists And Uses Thereofapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.